Intravitreal crystalline drug delivery for intraocular proliferation diseases. - Wikidata - awgldk - TriplyDB

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

http://www.wikidata.org/entity/Q33847455

about

A novel peptide derived from human pancreatitis-associated protein inhibits inflammation in vivo and in vitro and blocks NF-kappa B signaling pathway Protein kinase Cα downregulation via siRNA-PKCα released from foldable capsular vitreous body in cultured human retinal pigment epithelium cells.Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.Inhibitory effect of a novel peptide, H-RN, on keratitis induced by LPS or poly(I:C) in vitro and in vivo via suppressing NF-κB and MAPK activation.Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.Prodrug strategies in ocular drug delivery.Medicinal Chemistry of the Noncanonical Cyclic Nucleotides cCMP and cUMP.A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy.Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.Sustained protection against photoreceptor degeneration in tubby mice by intravitreal injection of nanoceria.A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies.

P2860

Q34110775-89A4ABC6-158E-46A7-8B08-ED1C99F060FF Q35090497-F5833D63-5AF2-4DDA-807C-7223BA8563B2 Q35164657-1A47BE75-DF34-436D-B622-490703E9DDE0 Q35560465-C988E0D5-1305-492D-9089-DB4E0EDD2F3D Q35648048-FAEEAFBF-EFD2-4063-A406-D8AF69A28B38 Q36620642-87531B5D-4891-4FEC-AB9D-D96559482E28 Q37609648-B621FB61-5B0D-4D61-88C1-CA792CD24848 Q37633935-0EF9B005-1D57-4E85-8353-BC3C7C468E14 Q38005228-DF53659D-F993-4784-A5E6-6C1365B1532B Q38789622-EC47042D-255C-4672-8FC6-F938880A2223 Q39300347-E19DA400-B9CD-45A6-A88E-CE5123BE13EC Q41348682-2D7929AF-31A4-403E-90C1-50499293B263 Q42019986-6BA2FED1-DDEF-484D-9653-CB2EC7BE97C9 Q46124251-01416DFE-19D5-4A2D-A2C1-9D62BBCD5170 Q49815957-CE417564-6D51-4E5F-8E8B-A957B4A473CE

P2860

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

http://www.wikidata.org/entity/Q33847455

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

@ast

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

@en

type

label

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

@ast

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

@en

prefLabel

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

@ast

Intravitreal crystalline drug delivery for intraocular proliferation diseases.

@en

P1433

Q33847455-4EAECC8C-DBE5-468C-9704-C02EC366246F

P1476

Q33847455-97E9EBE2-5630-465D-A904-ECB1B03259EE

P2093

Q33847455-19DE89EC-2FFB-4F62-85F5-C1F3E126F4EA

Q33847455-1D3E5FA2-724B-48FB-99D2-50B40664176F

Q33847455-43B3109C-0D5B-4823-86AB-803F650A567D

Q33847455-85E1CA50-FC76-42E0-8E16-946278D0B35D

Q33847455-AE0E0EE4-9893-47EB-BCEC-77C3500D00F2

Q33847455-C5D4424E-88F7-443A-8C55-AC2681E3EB84

Q33847455-CC1B4E5F-1459-4DCC-BC99-FDA4B26015CE

Q33847455-E101E0AC-F41F-43B2-B2AE-343C2B4D3089

P2860

Q33847455-0F8C0694-0B2D-44AF-959C-A6647D5FE1A1

Q33847455-1E94861E-A037-4290-8092-B695560847E1

Q33847455-1FBC1B09-C94C-45F0-8800-A4A229DC6ED5

Q33847455-20B404A7-A97D-45F0-9D0F-B6FD056ED1D9

Q33847455-25C59B37-556C-44EC-9D55-9CEA8EBC90A1

Q33847455-327CC602-A613-4452-8590-D4DAA894524D

Q33847455-463664F8-34CF-4CE0-AFCE-DAED60FE2141

Q33847455-4B48E6B0-25F0-4B31-B448-1DCCD4C39D80

Q33847455-4CF76DC8-659B-4896-BA02-A8FAA37D998F

Q33847455-5C69AD6F-E6D0-44BD-B513-DAD9B764486D

P304

Q33847455-7CCB72B4-035C-4033-B217-75E8709AF582

P31

Q33847455-94B340D5-A68C-413B-A8CA-6C640291F56B

P356

Q33847455-78D9DAA7-61B5-40A3-91F5-0ACE29210054

P407

Q33847455-91FFB5E1-8561-411A-8A9A-F7E5660E6BC1

P433

Q33847455-00C9B2ED-DA31-4D61-91ED-2E8879C1C5C5

P478

Q33847455-22155A0A-CFC8-459F-80B4-188C115D6234

P50

Q33847455-993D2049-E17C-4FC3-95D9-B30578C1D90F

P577

Q33847455-E70F6E5E-E06E-4ED7-948E-FD28257986EF

P5875

Q33847455-685819FC-FE40-4B73-BEDC-5B5C59DDC637

P698

Q33847455-73224886-924A-4E1D-BD51-0024F975A899

P921

Q33847455-1CAABA6D-72D4-4189-9289-A4016A298DB4

P932

Q33847455-CE92B2B3-30DA-4069-AC9F-817AF1C09EF4

P356

P1433

Investigative Ophthalmology & Visual Science

P1476

Intravitreal crystalline drug delivery for intraocular proliferation diseases

@en

P2093

Ajay Tammewar

http://www.w3.org/2001/XMLSchema#string

Dirk-Uwe Bartsch

http://www.w3.org/2001/XMLSchema#string

Iryna Falkenstein

http://www.w3.org/2001/XMLSchema#string

James Beadle

http://www.w3.org/2001/XMLSchema#string

Kathy Aldern

http://www.w3.org/2001/XMLSchema#string

Lingyun Cheng

http://www.w3.org/2001/XMLSchema#string

Nadya Valiaeva

http://www.w3.org/2001/XMLSchema#string

William R Freeman

http://www.w3.org/2001/XMLSchema#string

P2860

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review

Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

The prevalence of low vision and blindness in Canada.

Effects of intravitreal triamcinolone acetonide injection with and without preservative.

Age-related macular degeneration and choroidal neovascularization.

The application of the macular photocoagulation study eligibility criteria for laser treatment in age-related macular degeneration.

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Proliferative vitreoretinopathy as a late complication of blunt ocular trauma.

A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.

P304

474-481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1167/IOVS.09-3672

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Karl Y Hostetler

P577

2009-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26756652

http://www.w3.org/2001/XMLSchema#string

P698

19696179

http://www.w3.org/2001/XMLSchema#string

P921

P932

2869063

http://www.w3.org/2001/XMLSchema#string